Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173805 | 0.81 | HTR3A (0.43) | FFAR1 | |
| SCHEMBL3164293 | 0.81 | FFAR1 (0.38) | TERTFFAR1MAP2K7 | |
| SCHEMBL7138279 | 0.75 | FFAR1 (0.46) | ALDH1A1SMN1; SMN2FFAR1MAPT | |
| SCHEMBL4979464 | 0.75 | BRD4 (0.47) | ALDH1A1SMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL17640683 | 0.75 | MAPT (0.52) | ALDH1A1SMN1; SMN2TERTL3MBTL1MEN1 | |
| SCHEMBL24779093 | 0.74 | NPC1 (0.51) | ALDH1A1SMN1; SMN2TERTL3MBTL1MEN1 | |
| SCHEMBL21135465 | 0.73 | HPGD (0.49) | ALDH1A1SMN1; SMN2FFAR1MAPT | |
| SCHEMBL11873635 | 0.73 | ADORA2A (0.41) | ALDH1A1SMN1; SMN2TERTFFAR1L3MBTL1 | |
| SCHEMBL27918373 | 0.73 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL27937022 | 0.73 | FFAR1 (0.50) | ALDH1A1FFAR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7341709-B2 | Compositions for labeling β-amyloid plaques and neurofibrillary tangles | REGENTS OF UNIVERSITY OF CALIFORNIA (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070053831-A1 | Methods for binding agents to b-amyloid plaques | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-03-08 | — | — | US | disclosed |
| US-20040072371-A1 | Compositions for labeling beta-amyloid plaques and neurofibrillary tangles | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2004-04-15 | — | — | US | disclosed |
| US-6660530-B2 | Diagnosis of Alzheimer's disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-12-09 | — | — | US | disclosed |
| US-20020022002-A1 | Methods for labeling beta-amyloid plaques and neurofibrillary tangles | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-02-21 | — | — | US | disclosed |
| US-6274119-B1 | LABELING .BETA.-AMYLOID PLAQUES AND NEUROFIBRILLARY TANGLES IN VIVO AND IN VITRO, COMPRISES CONTACTING RADIOLABELED AMINONAPTHALENE DERIVATIVE WITH MAMMALIAN TISSUE | THE REGENTS OF THE UNIV. OF CALIFORNIA | 2001-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022002-A1 | Methods for labeling beta-amyloid plaques and neurofibrillary tangles | OXSR1, MSR1, CBR1 | ALDH1A1 2172/4885SMN1; SMN2 1122/4885TERT 1377/4885 |
| US-20070053831-A1 | Methods for binding agents to b-amyloid plaques | APBA1, CLTB, FABP7 | ALDH1A1 4658/4885SMN1; SMN2 2050/4885TERT 2887/4885 |
| US-20040072371-A1 | Compositions for labeling beta-amyloid plaques and neurofibrillary tangles | CBR1, CBR3, MSR1 | ALDH1A1 2622/4885SMN1; SMN2 1553/4885TERT 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.